You are now being logged in using your Facebook credentials

Anti-Tobacco Group

Anti-Tobacco Group
Category:
Created:
Friday, 05 August 2011
Group Admins:
Every day, thousands adolescents light up their first cigarette across the world . From the American Cancer Society: • Eighty-nine percent of people who ever try a cigarette try by age 18. Almost no one starts the smoking habit during adulthood. • Seventy percent of adolescent smokers say they would never have started if they could choose again. That's because the nicotine in cigarettes is addictive. The risk of becoming addicted to nicotine is between one in two and one in three. • Tobacco is responsible for nearly one in every five deaths in the United States. It is the largest cause of preventable death. More than 400,000 people die every year from smoking-related diseases. That's more than from alcohol, crack, heroin, murder, suicide, car accidents, and AIDS combined! What can we do?
There are no announcements yet.
A nice article. In my opinion, our Group should move forward to globally spread the message that "any form of Nicotine is addictive and harmful to humanity" - including the E-Cigarettes.
Last replied by V Regunathan on Saturday, 03 November 2012
It might be questioned if Propylene Glycol is safe as a main substance in e-cigarettes. Today I would like to discuss about it. Propylene glycol is a solvent of some medications such as Benzodiazepines. Wilson and his colleagues in Boston showed that propylene glycol toxicity is a potentially life-threatening iatrogenic complication. Although, they did not evaluate inhaler complications of e-cigarettes, the systemic effects of propylene glycol probably is the similar. Please find more detail here. Chest. 2005 Sep;128(3):1674-81. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Wilson KC, Reardon C, Theodore AC, Farber HW. Source The Pulmonary Center, R-304, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA. kwilson@lung.bumc.bu.edu Abstract STUDY OBJECTIVES: Benzodiazepines are commonly administered to medical ICU (MICU) patients. Propylene glycol (1,2-propanediol) is the solvent used to deliver lorazepam and diazepam IV. Although propylene glycol toxicity is increasingly recognized and reported, its incidence is unknown. Herein, we describe five MICU patients who acquired severe propylene glycol toxicity due to IV lorazepam or diazepam administration. Additionally, we evaluate the incidence of propylene glycol toxicity in MICU patients receiving IV lorazepam or diazepam. DESIGN: Case series and prospective, observational study. SETTING: Eighteen-bed MICU in a 550-bed urban academic hospital. PATIENTS AND METHODS: MICU patients administered IV benzodiazepines during a 3-month period were enrolled. Patients were categorized according to the IV benzodiazepine that they received. Laboratory data and highlights of their clinical course were recorded daily. The incidence of propylene glycol toxicity was determined and the groups compared. RESULTS: Forty-four patients were enrolled. Twenty-one patients received a benzodiazepine delivered in propylene glycol (lorazepam or diazepam), and 23 patients received a benzodiazepine delivered in an alternative solvent (midazolam). We found that four patients (19%) who received IV lorazepam or diazepam had metabolic evidence of propylene glycol toxicity. None of the patients had clinical deterioration. Neither metabolic abnormality nor clinical deterioration suggestive of propylene glycol toxicity were identified in subjects receiving IV midazolam. CONCLUSION: Propylene glycol toxicity is a potentially life-threatening iatrogenic complication that is common and preventable. It should be considered whenever a patient has an unexplained anion gap, unexplained metabolic acidosis, hyperosmolality, and/or clinical deterioration. Close monitoring of all patients receiving IV lorazepam or diazepam for early evidence of propylene glycol toxicity is warranted.
Last replied by Mehdi Mirsaeidi on Sunday, 21 August 2011

Legal Information

Other Information

Contact Information

51-53 Mount Pleasant, London, WC1X 0AE
Telephone: +44 207 278 7072
Email: info@3four50.com